Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages

키워드

참고문헌 (96)

1. "Draft landscape of COVID-19 candidate vaccines"[URL]
2. 이푸름, "Newly Emerging Human Coronaviruses: Animal Models and Vaccine Research for SARS, MERS, and COVID-19", Immune Network, 20(4), pp.1~25 (2020), 대한면역학회[DOI]
3. Gu H, "Adaptation of SARSCoV-2 in BALB", c mice for testing vaccine efficacy, 2020, pp.369, 1603~1607
4. Wrapp D, "Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation", Science, 367, pp.1260~1263 (2020)
5. Hamming I, "Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis", J Pathol, 203, pp.631~637 (2004)
6. Corbett KS, "SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness", Nature, 586, pp.567~571 (2020)
7. "mRNA based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus neutralizing antibodies and mediates protection in rodents"[URL]
8. Smith TR, "Immunogenicity of a DNA vaccine candidate for COVID-19", Nat Commun, 11, pp.2601~ (2020)
9. van Doremalen N, "ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2pneumonia in rhesus macaques", Nature, 586, pp.578~582 (2020)
10. Mercado NB, "Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques", Nature, 586, pp.583~588 (2020)
11. Logunov DY, "Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations : two open, nonrandomised phase 1", 2 studies from Russia, 2020, pp.396, 887~897
12. Guebre-Xabier M, "NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge", Vaccine, 38, pp.7892~7896 (2020)
13. Bosch BJ, "The coronavirus spike protein is a class I virus fusion protein : structural and functional characterization of the fusion core complex", J Virol, 77, pp.8801~8811 (2003)
14. Shang J, "Cell entry mechanisms of SARS-CoV-2", Proc Natl Acad Sci U S A, 117, pp.11727~11734 (2020)
15. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271.e8~280.e8 (2020)
16. Cai Y, "Distinct conformational states of SARS-CoV-2 spike protein", Science, 369, pp.1586~1592 (2020)
17. Sanders RW, "Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1", J Virol, 76, pp.8875~8889 (2002)
18. Impagliazzo A, "A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen", Science, 349, pp.1301~1306 (2015)
19. Kong L, "Uncleaved prefusion-optimized gp140 trimers derived from analysis of HIV-1 envelope metastability", Nat Commun, 7, pp.12040~ (2016)
20. Pallesen J, "Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen", Proc Natl Acad Sci U S A, 114, pp.E7348~E7357 (2017)
21. Shi R, "A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2", Nature, 584, pp.120~124 (2020)
22. Grant OC, "Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition", Sci Rep, 10, pp.14991~ (2020)
23. Dai L, "A universal design of Betacoronavirus vaccines against COVID-19, MERS, and SARS", Cell, 182, pp.722.e11~733.e11 (2020)
24. Walls AC, "Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2", Cell, 183, pp.1367.e17~1382.e17 (2020)
25. Bennett NR, "Multivalent antigens for promoting b and t cell activation", ACS Chem Biol, 10, pp.1817~1824 (2015)
26. Irvine DJ, "Engineering synthetic vaccines using cues from natural immunity", Nat Mater, 12, pp.978~990 (2013)
27. Sun J, "Generation of a broadly useful model for COVID-19 pathogenesis, vaccination, and treatment", Cell, 182, pp.734.e5~743.e5 (2020)
28. Sariol A, "Lessons for COVID-19 immunity from other coronavirus infections", Immunity, 53, pp.248~263 (2020)
29. Zuwała K, "The nucleocapsid protein of human coronavirus NL63", PLoS One, 10, pp.e0117833~ (2015)
30. Grifoni A, "A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2", Cell Host Microbe, 27, pp.671.e2~680.e2 (2020)
31. Zhao J, "Airway memory CD4+T cells mediate protective immunity against emerging respiratory coronaviruses", Immunity, 44, pp.1379~1391 (2016)
32. Yasui F, "Prior immunization with severe acute respiratory syndrome(SARS)-associated coronavirus(SARS-CoV)nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV", J Immunol, 181, pp.6337~6348 (2008)
33. Pardi N, "Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination", Nature, 543, pp.248~251 (2017)
34. Bahl K, "Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses", Mol Ther, 25, pp.1316~1327 (2017)
35. Schnee M, "An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs", PLoS Negl Trop Dis, 10, pp.e0004746~ (2016)
36. Pardi N, "mRNA vaccines-a new era in vaccinology", Nat Rev Drug Discov, 17, pp.261~279 (2018)
37. Jackson NA, "The promise of mRNA vaccines : a biotech and industrial perspective", NPJ Vaccines, 5, pp.11~ (2020)
38. Baden LR, "Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine", N Engl J Med, 384, pp.403~416 (2021)
39. Corbett KS, "Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates", N Engl J Med, 383, pp.1544~1555 (2020)
40. Jackson LA, "An mRNA vaccine against SARS-CoV-2-preliminary report", N Engl J Med, 383, pp.1920~1931 (2020)
41. Walsh EE, "Safety and immunogenicity of two RNA-based COVID-19 vaccine candidates", N Engl J Med, 383, pp.2439~2450 (2020)
42. "A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates"[URL]
43. Polack FP, "Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine", N Engl J Med, 383, pp.2603~2615 (2020)
44. "Phase 1 assessment of the safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 in human volunteers"[URL]
45. Zhu FC, "Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine : a doseescalation, open-label, non-randomised, first-in-human trial", Lancet, 395, pp.1845~1854 (2020)
46. Folegatti PM, "Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1", 2, single-blind, randomised controlled trial, 2020, pp.396, 467~478
47. Voysey M, "Safety and efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222)against SARS-CoV-2 : an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", Lancet, 397, pp.99~111 (2021)
48. Bos R, "Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 spike immunogen induces potent humoral and cellular immune responses", NPJ Vaccines, 5, pp.91~ (2020)
49. "Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate:interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial"[URL]
50. Xia S, "Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes : interim analysis of 2randomized clinical trials", JAMA, 324, pp.951~960 (2020)
51. Xia S, "Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV : a randomised, double-blind, placebo-controlled, phase 1", 2 trial, 2021, pp.21, 39~51
52. Gao Q, "Development of an inactivated vaccine candidate for SARS-CoV-2", Science, 369, pp.77~81 (2020)
53. Zhang Y, "Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years : a randomised, double-blind, placebo-controlled, phase 1", 2 clinical trial, 2020, pp.21, 181~192
54. Keech C, "Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine", N Engl J Med, 383, pp.2320~2332 (2020)
55. Nicoli F, "HPV-specific systemic antibody responses and memory b cells are independently maintained up to 6 years and in a vaccine-specific manner following immunization with cervarix and gardasil in adolescent and young adult women in vaccination programs in Italy", Vaccines(Basel), 8, pp.26~ (2020)
56. "Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARSCoV-2 challenge model"[URL]
57. Tebas P, "Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2 : a preliminary report of an open-label, phase 1 clinical trial", EClinicalMedicine, 31, pp.100689~ (2020)
58. "Preclinical study of DNA vaccines targeting SARS-CoV-2"[URL]
59. Plotkin SA, "Vaccines : correlates of vaccine-induced immunity", Clin Infect Dis, 47, pp.401~409 (2008)
60. Cheng Y, "Use of convalescent plasma therapy in SARS patients in Hong Kong", Eur J Clin Microbiol Infect Dis, 24, pp.44~46 (2005)
61. Yeh KM, "Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital", J Antimicrob Chemother, 56, pp.919~922 (2005)
62. Wang W, "Generation of a protective murine monoclonal antibody against the stem of influenza hemagglutinins from group 1 viruses and identification of resistance mutations against it", PLoS One, 14, pp.e0222436~ (2019)
63. Bloch EM, "Deployment of convalescent plasma for the prevention and treatment of COVID-19", J Clin Invest, 130, pp.2757~2765 (2020)
64. Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
65. Liu X, "High-dose intravenous immunoglobulins in the treatment of severe acute viral pneumonia : the known mechanisms and clinical effects", Front Immunol, 11, pp.1660~ (2020)
66. Tomaras GD, "HIV-1-specific antibody responses during acute and chronic HIV-1 infection", Curr Opin HIV AIDS, 4, pp.373~379 (2009)
67. Cobey S, "Immune history and influenza virus susceptibility", Curr Opin Virol, 22, pp.105~111 (2017)
68. Saphire EO, "Antibody-mediated protection against Ebola virus", Nat Immunol, 19, pp.1169~1178 (2018)
69. Barrett JR, "Phase 1", 2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, 2021, pp.27, 279~288
70. Yu J, "DNA vaccine protection against SARS-CoV-2 in rhesus macaques", Science, 369, pp.806~811 (2020)
71. Atyeo C, "Distinct early serological signatures track with SARS-CoV-2 survival", Immunity, 53, pp.524.e4~532.e4 (2020)
72. Chen J, "Cellular immune responses to severe acute respiratory syndrome coronavirus(SARS-CoV)infection in senescent BALB", c mice : CD4+T cells are important in control of SARS-CoV infection, 2010, pp.84, 1289~1301
73. Zhao J, "T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice", J Virol, 84, pp.9318~9325 (2010)
74. Zhao J, "Rapid generation of a mouse model for Middle East respiratory syndrome", Proc Natl Acad Sci U S A, 111, pp.4970~4975 (2014)
75. Mathew D, "Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications", Science, 369, pp.eabc8511~ (2020)
76. Sekine T, "Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19", Cell, 183, pp.158.e14~168.e14 (2020)
77. "Establishment of the who international standard and reference panel for anti-SARS-CoV-2 antibody"[URL]
78. Altmann DM, "SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection", Sci Immunol, 5, pp.eabd6160~ (2020)
79. Kim HW, "Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine", Am J Epidemiol, 89, pp.422~434 (1969)
80. De Swart RL, "Immunization of macaques with formalin-inactivated respiratory syncytial virus(RSV)induces interleukin-13-associated hypersensitivity to subsequent RSV infection", J Virol, 76, pp.11561~11569 (2002)
81. Halstead SB, "Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody", J Exp Med, 146, pp.201~217 (1977)
82. Dejnirattisai W, "Cross-reacting antibodies enhance dengue virus infection in humans", Science, 328, pp.745~748 (2010)
83. Kliks SC, "Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants", Am J Trop Med Hyg, 38, pp.411~419 (1988)
84. Rothman AL, "Immunity to dengue virus : a tale of original antigenic sin and tropical cytokine storms", Nat Rev Immunol, 11, pp.532~543 (2011)
85. Weingartl H, "Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets", J Virol, 78, pp.12672~12676 (2004)
86. Bolles M, "A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge", J Virol, 85, pp.12201~12215 (2011)
87. Takano T, "Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection", J Vet Med Sci, 70, pp.1315~1321 (2008)
88. Weiss RC, "Antibody-mediated enhancement of disease in feline infectious peritonitis : comparisons with dengue hemorrhagic fever", Comp Immunol Microbiol Infect Dis, 4, pp.175~189 (1981)
89. Joyner MJ, "Safety update : COVID-19 convalescent plasma in 20, 000 hospitalized patients", Mayo Clin Proc, 95, pp.1888~1897 (2020)
90. Braun J, "SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19", Nature, 587, pp.270~274 (2020)
91. Grifoni A, "Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals", Cell, 181, pp.1489.e15~1501.e15 (2020)
92. Nienen M, "The role of pre-existing cross-reactive central memory CD4 T-cells in vaccination with previously unseen influenza strains", Front Immunol, 10, pp.593~ (2019)
93. Abreu RB, "Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination", JCI Insight, 5, pp.e132155~ (2020)
94. "Preexisting memory CD4 T cells in naïve individuals confer robust immunity upon vaccination"[URL]
95. Gorse GJ, "Prevalence of antibodies to four human coronaviruses is lower in nasal secretions than in serum", Clin Vaccine Immunol, 17, pp.1875~1880 (2010)
96. Ng KW, "Preexisting and de novo humoral immunity to SARS-CoV-2 in humans", Science, 370, pp.1339~1343 (2020)

관련 논문AI추천